Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School

Fortress Biotech (NASDAQ:FBIO), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that its subsidiary, Aevitas Therapeutics, has entered into a sponsored research agreement with the laboratory of Guangping Gao, Ph.D., at the University of Massachusetts Medical School. The SRA will evaluate construct optimization in the development of gene therapies based on Aevitas’ adeno-associated virus technology.

As quoted in the press release:

Lindsay A. Rosenwald, M.D., Fortress Biotech’s Chairman, President and Chief Executive Officer, said, “Dr. Gao is a world-renowned AAV gene therapy researcher who has made significant contributions to the development of safer and more effective AAV-based treatments. We look forward to leveraging his expertise as part of Aevitas’ newly formed scientific advisory board, and through the research agreement with UMass Medical School, which will enable Aevitas to advance potentially lifelong treatments for complement-mediated diseases toward the clinic.”

Click here to read the full press release.